Summary
Affimed N.V. (A28A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Affimed N.V. ever had a stock split?
Affimed N.V. Profile
| Biotechnology Industry | Healthcare Sector | Shawn Leland CEO | XMUN Exchange | - ISIN |
| DE Country | 76 Employees | - Last Dividend | 11 Mar 2024 Last Split | - IPO Date |
Overview
Affimed N.V. is a clinical-stage biopharmaceutical entity deeply entrenched in the innovation and development of cancer immunotherapies. With operational bases in both the United States and Germany, the company seeks to pioneer in creating therapeutic solutions targeting various forms of cancer. Initially established under the name Affimed Therapeutics B.V., the company underwent a rebranding to Affimed N.V. in October 2014, marking a significant evolution in its corporate identity since its foundation in the year 2000. Its collaborations span notable entities such as Artiva Biotherapeutics, Roivant Sciences Ltd., and Genentech, showcasing a commitment to leveraging synergies for advancing its research and development endeavors in oncology.
Products and Services
AFM13: A leading product candidate by Affimed, AFM13 is designed to target CD30-positive lymphoma. It has successfully completed a Phase 2 clinical trial, demonstrating its utility in addressing this form of cancer. Additionally, AFM13 has been evaluated in a Phase Ib clinical trial for hodgkin lymphoma and completed a Phase IIb clinical study targeting peripheral T-cell lymphoma, highlighting its versatility and potential in oncology treatment.
AFM24: This innovative product candidate stands out as a tetravalent, bispecific engager of the epidermal growth factor receptor (EGFR) and CD16A, intended to stimulate the innate immune system against advanced cancers. Currently, AFM24 is progressing through a Phase IIa clinical trial, embodying Affimed's commitment to expanding its therapeutic portfolio against a variety of malignancies.
AFM28: Affimed is also pioneering the development of AFM28, an innate cell engager (ICE) in the preclinical development stage. Specifically formulated for the treatment of acute myeloid leukemia (AML), AFM28 exemplifies the company's ongoing pursuit of novel approaches to combatting blood cancers.
AFM32: Representing another preclinical development endeavor, AFM32 is an ICE candidate focused on the treatment of solid tumors. Encompassing a broad potential in oncology, this product candidate further solidifies Affimed's role in pushing the boundaries of cancer treatment. Through a license and strategic collaboration agreement with Roivant Sciences Ltd., AFM32 is poised to add significant depth to the company's pipeline of innovative cancer therapies.
